Industry

SEATTLE–(BUSINESS WIRE)–#earnings–NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today announced that the Company will report third quarter 2022 operating results after the close of the market on Monday, November 7, 2022. Company management will host a conference call beginning at 4:30pm ET to discuss those results … [Read more…]

New data reinforces the performance of the Nodify XL2® proteomic test in assessing risk of malignancy of pulmonary nodules in different patient populations BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst–Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus in lung disease, announced today that three data presentations will occur at the CHEST 2022 Annual … [Read more…]

The first and only physician in the country to achieve milestone of 2,000 endoscopic sleeve gastroplasty procedures will address questions in real-time CARY, N.C.–(BUSINESS WIRE)–Dr. Christopher McGowan, CEO and Medical Director of True You Weight Loss, will livestream his 2000th Endoscopic Sleeve Gastroplasty on Saturday, October 15th, allowing prospective patients and physician colleagues from around … [Read more…]

Dr. Bille will oversee manufacturing scale-up for broad-spectrum influenza vaccine candidate OVX836 currently in Phase 2 clinical testing Company achieved accreditation from Belgian authorities for OVX836 batch quality control laboratory in Liège Science Park LYON, France–(BUSINESS WIRE)–Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, today announced … [Read more…]

COPENHAGEN, Denmark–(BUSINESS WIRE)–Liva Health, one of Europe’s leading evidence-based digital health coaching providers, is pleased to announce the appointment of Shahram Sharif as its new group CEO. Sharif will focus on Liva Health’s ambition of scaling up its digital services of tackling chronic conditions through digital tools that deliver significant clinical outcomes, affordably at scale. … [Read more…]

– Isaralgagene civaparvovec, or ST-920, continued to be generally well tolerated across four dose cohorts in the nine treated patients in the dose escalation phase. – All nine patients exhibited elevated α-Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date … [Read more…]

The LifePort Kidney Transporter selected as the exclusive hypothermic machine perfusion technology for donor kidney preservation at all national transplantation centers in Belgium. ITASCA, Ill.–(BUSINESS WIRE)–Surgeons at Universitaire Ziekenhuizen and AZ Universitair Ziekenhuis have successfully performed the first kidney transplant procedures as part of a national contract with Organ Recovery Systems that designates the Company … [Read more…]

Late-Breaking Abstract Selected for Oral Presentation, November 7th Phase 2 for PXL065 in NASH achieved the primary efficacy endpoint for liver fat content reduction for all doses and showed strong improvement in fibrosis without worsening of NASH LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext : POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for … [Read more…]

SIX Exchange Regulation approves delisting of Vifor Pharma AG’s registered shares The totality of the registered shares will be delisted following the legally binding court decision regarding the cancellation of the remaining publicly held registered shares ST. GALLEN, SWITZERLAND–(BUSINESS WIRE)–Regulatory News: AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR Vifor Pharma AG (SWX:VIFN) (Vifor) announced … [Read more…]

– New two-year Evrysdi data show improvement or maintenance of motor function in people with SMA, a progressive neuromuscular disease that can be fatal – – The JEWELFISH study enrolled the broadest and most diverse patient population ever studied in an SMA trial – – Longer-term safety data consistent with that previously seen in earlier … [Read more…]